STAMBP-IN-1

• UNSPSC Description:

  STAMBP-IN-1 is a small-molecule inhibitor of STAMBP deubiquitinase, and interrupts STAMBP-Ub-NALP7 interaction. STAMBP-IN-1 decreases protein level of its inflammasome substrate NALP7 and suppresses IL-1b release after Toll-like receptor (TLR) agonism. STAMBP-IN-1 inhibits the activity of STAMBP to cleave recombinant di-Ub with an IC50 value of 0.33 mM[1].

• Target Antigen:

  Deubiquitinase

• Type:

  Reference compound

• Related Pathways:

  Cell Cycle/DNA Damage

• Applications:

  COVID-19-anti-virus

• Field of Research:

  Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/stambp-in-1.html

• Solubility:

  DMSO : 3.29 mg/mL (warming;heat to 80°C)

• Smiles:

  O=C(NCC1=CC=CO1)CSC(N2CCC3=CC=CC=C3)=NC4=C(C=C(N5CCOCC5)C=C4)C2=O

• Molecular Weight:

  504.60

• References & Citations:

  [1]Bednash JS,et al. Targeting the deubiquitinase STAMBP inhibits NALP7 inflammasome activity. Nat Commun. 2017 May 11;8:15203.

• Shipping Conditions:

  Room Temperature

• Clinical Information:

  No Development Reported

• CAS Number:

  896683-78-6